Published in Cancer Chemother Pharmacol on January 01, 1986
Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action. Br J Pharmacol (2004) 0.80
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol (1999) 12.42
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
The composite genome of the legume symbiont Sinorhizobium meliloti. Science (2001) 9.11
Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ (1994) 3.52
Management of adult acute myelogenous leukaemia. Br Med J (1973) 3.33
The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med (1986) 3.27
Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol (1992) 3.25
Antisera to acute lymphoblastic leukemia cells. Clin Immunol Immunopathol (1975) 3.12
Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol (1994) 2.94
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2001) 2.71
The human type-C retrovirus, HTLV, in Blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma. Int J Cancer (1982) 2.71
Immunotherapy for acute myelogenous leukaemia. Br J Cancer (1973) 2.67
Rapid diagnosis of cytomegalovirus infection in immunocompromised patients by detection of early antigen fluorescent foci. Lancet (1984) 2.65
The epidemiology of Clostridium difficile with use of a typing scheme: nosocomial acquisition and cross-infection among immunocompromised patients. J Infect Dis (1986) 2.61
Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst (1989) 2.58
The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology (2000) 2.51
Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet (1982) 2.51
Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia. Br Med J (1970) 2.51
The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. Hematol J (2000) 2.34
Safety and activity of saquinavir in HIV infection. Lancet (1995) 2.32
Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol (2000) 2.29
Central nervous system relapse in acute promyelocytic leukaemia in patients treated with all-trans retinoic acid. Br J Haematol (1997) 2.27
Use of panels of monoclonal antibodies in the differential diagnosis of neuroblastoma and lymphoblastic disorders. Lancet (1983) 2.26
Expression of human T and B lymphocyte cell-surface markers on leukaemic cells. Lancet (1974) 2.15
Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature. Bone Marrow Transplant (2002) 2.09
The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol (1988) 2.05
Stage I-II pediatric Hodgkin's disease: long-term follow-up demonstrates equivalent survival rates following different management schemes. J Clin Oncol (1990) 2.02
Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet (1982) 2.01
Parenteral acyclovir therapy for herpesvirus infections in man. Lancet (1979) 1.99
Adjuvant low dose radiation in childhood T cell leukaemia/lymphoma (report from the United Kingdom Childrens' Cancer Study Group--UKCCSG). Br J Cancer (1984) 1.97
Developmentally regulated rearrangement and expression of genes encoding the T cell receptor-T3 complex. Cell (1986) 1.96
An orbital period of 0.94 days for the hot-Jupiter planet WASP-18b. Nature (2009) 1.79
Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol (2001) 1.79
Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood (1992) 1.77
Immunological analysis of the skin in graft versus host disease. Clin Exp Immunol (1982) 1.76
Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma (2006) 1.74
Pre-induction LDH as a prognostic factor for outcome of high dose chemotherapy (HDCT) for germ cell tumours relapsing or refractory to conventional chemotherapy. Br J Cancer (2000) 1.74
Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br J Haematol (1997) 1.72
Emotional support for cancer patients: what do patients really want? Br J Cancer (1996) 1.72
Hypoparathyroidism and hypocalcaemia during treatment for acute leukaemia. Br Med J (Clin Res Ed) (1982) 1.72
The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol (2000) 1.68
Iron metabolism in patients undergoing regular dialysis therapy. Br Med J (1971) 1.67
Combination chemotherapy in generalized Hodgkin's disease. Br Med J (1970) 1.67
Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. Br Med J (Clin Res Ed) (1983) 1.67
Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet (1983) 1.66
A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol (1999) 1.66
Array-based DNA methylation profiling in follicular lymphoma. Leukemia (2009) 1.63
Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol (2003) 1.59
Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med (1999) 1.59
The human hematopoietic stem cell in vitro and in vivo. Blood Cells (1992) 1.58
Central nervous system toxicity of interferon. Br J Cancer (1983) 1.58
Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant (1998) 1.58
The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J Clin Oncol (1991) 1.55
Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia. Lancet (1982) 1.55
ETV6/AML1 fusion by FISH in adult acute lymphoblastic leukemia. Leukemia (2002) 1.54
Daunorubicin in acute myelocytic leukaemia. Lancet (1969) 1.54
Combined chemotherapy versus melphalan and prednisolone for treatment of myelomatosis. Lancet (1992) 1.52
Cytotoxic-induced ovarian failure in women with Hodgkin's disease. I. Hormone function. JAMA (1979) 1.52
Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol (1985) 1.51
Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet (1984) 1.51
Incidence and outcome of critical illness amongst hospitalised patients with haematological malignancy: a prospective observational study of ward and intensive care unit based care. Anaesthesia (2005) 1.50
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother (1991) 1.50
Solitary plasmacytoma. I: Extramedullary soft tissue plasmacytoma. Cancer (1979) 1.50
Trisomy 14 is a non-random karyotypic abnormality associated with myeloid malignancies. Br J Haematol (1997) 1.49
Clinical significance of skin biopsies in the diagnosis and management of graft-vs-host disease in early postallogeneic bone marrow transplantation. Arch Dermatol (2000) 1.48
Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol (1995) 1.48
High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Ann Oncol (1998) 1.48
MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J (1978) 1.46
Testicular relapse of acute promyelocytic leukemia after allogeneic BMT. Bone Marrow Transplant (1997) 1.45
Rubidomycin in acute leukaemia in adults. Br Med J (1968) 1.45
Prevalence and clinical correlations of MLL gene rearrangements in AML-M4/5. Blood (1994) 1.44
Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol (2000) 1.43
Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient. Br J Cancer (1977) 1.43
HLA-DP based resistance to Hodgkin's disease. Lancet (1989) 1.42
Angio-immunoblastic lymphadenopathy: report of ten cases and review of the literature. Q J Med (1979) 1.42
Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol (1994) 1.41
Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse. Am J Pathol (1983) 1.40
Apparent removal of graft-versus-leukaemia effect by the use of leucocyte-poor blood components in patients with acute myeloblastic leukaemia. Br J Haematol (1989) 1.40
L-asparaginase in treatment of acute leukaemia and lymphosarcoma. Br Med J (1970) 1.39
Two blueprints for the future: cancer services in England and Wales. J R Coll Physicians Lond (2001) 1.39
Stomatococcus mucilaginosus: an emerging pathogen in neutropenic patients. Clin Infect Dis (1992) 1.39
Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial. Br Med J (Clin Res Ed) (1983) 1.37
Factors affecting reconstitution of the T cell compartment in allogeneic haematopoietic cell transplant recipients. Bone Marrow Transplant (2003) 1.37
Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol (2000) 1.36
Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant (1992) 1.36
Ethics and pharmaceutical medicine -- the full report of the Ethical Issues Committee of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the UK. Int J Clin Pract (2006) 1.34
Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol (1986) 1.34
T cell subpopulations, monoclonal antibodies and their therapeutic applications. Clin Haematol (1982) 1.34
Prolonged access to the venous system using the Hickman right atrial catheter. Ann R Coll Surg Engl (1983) 1.34